Biphenyl compounds useful as muscarinic receptor antagonists
This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar 1 , R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , and R 8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
1. A pharmaceutical composition comprising a pharmaceutically acceptable aqueous carrier and biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester or a pharmaceutically acceptable salt thereof.
2. The pharmaceutical composition of claim 1 , wherein the composition further comprises an agent selected from β 2 adrenergic receptor agonists, steroidal anti-inflammatory agents, phosphodiesterase-4 inhibitors, and combinations thereof.
3. The pharmaceutical composition of claim 2 , wherein the composition comprises a β 2 adrenergic receptor agonist and a steroidal anti-inflammatory agent.
4. The pharmaceutical composition of claim 1 , which is suitable for administration by inhalation.
5. The pharmaceutical composition of claim 1 , wherein the aqueous carrier is an isotonic aqueous solution.
6. The pharmaceutical composition of claim 5 , which is administered using a nebulizer inhaler.
7. The pharmaceutical composition of claim 6 , which comprises from about 0.05 μg/mL to about 10 mg/mL of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester or a pharmaceutically acceptable salt thereof.
8. The pharmaceutical composition of claim 2 , wherein the β 2 adrenergic receptor agonist is selected from salmeterol, salbutamol, formoterol, salmefamol, fenoterol, terbutaline, albuterol, isoetharine, metaproterenol, bitolterol, pirbuterol, levalbuterol, or a pharmaceutically acceptable salt or solvate thereof.
9. The pharmaceutical composition of claim 8 , wherein the β 2 adrenergic receptor agonist is salmeterol or a pharmaceutically acceptable salt or solvate thereof.
10. The pharmaceutical composition of claim 8 , wherein the β 2 adrenergic receptor agonist is formoterol or a pharmaceutically acceptable salt or solvate thereof.
11. The pharmaceutical composition of claim 2 , wherein the steroidal anti-inflammatory agent is selected from: methyl prednisolone; prednisolone; dexamethasone; fluticasone propionate; 6α,9α-difluoro-17α-[(2-furanylcarbonyl)oxy]-11β-hydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioic acid S-fluoromethyl ester; 6α,9α-difluoro-11β-hydroxy-16α-methyl-3-oxo-17α-propionyloxy-androsta-1,4-diene-17β-carbothioic acid S-(2-oxo-tetrahydrofuran-3S-yl) ester; beclomethasone esters; budesonide; flunisolide; mometasone esters; triamcinolone acetonide; rofleponide; ciclesonide; butixocort propionate; RPR-106541; ST-126; or a pharmaceutically acceptable salt or solvate thereof.
12. The pharmaceutical composition of claim 11 , wherein the steroidal anti-inflammatory agent is fluticasone propionate or a pharmaceutically acceptable solvate thereof.
13. The pharmaceutical composition of claim 11 , wherein the steroidal anti-inflammatory agent is budesonide.
14. The pharmaceutical composition of claim 2 , wherein the phosphodiesterase-4 inhibitor is selected from: cis 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-1-carboxylic acid; 2-carbomethoxy-4-cyano-4-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexan-1-one; cis-[4-cyano-4-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexan-1-ol]; and cis-4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid; or a pharmaceutically acceptable salt thereof.